Renaissance Technologies
AQST icon

Renaissance Technologies’s Aquestive Therapeutics AQST Stock Holding History

Renaissance Technologies’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-414,400
Closed -$2.68M – 3239
2025
Q4 		$2.68M Buy
414,400
+327,400
+376% +$2.04M ﹤0.01% 1688
2025
Q3 		$486K Buy
+87,000
New +$376K ﹤0.01% 2808
2025
Q1 		– Sell
-95,400
Closed -$340K – 3441
2024
Q4 		$340K Buy
95,400
+66,800
+234% +$308K ﹤0.01% 2994
2024
Q3 		$142K Sell
28,600
-467,600
-94% -$1.82M ﹤0.01% 3191
2024
Q2 		$1.29M Sell
496,200
-879,600
-64% -$2.94M ﹤0.01% 2174
2024
Q1 		$5.86M Buy
1,375,800
+104,300
+8% +$347K 0.01% 1314
2023
Q4 		$2.57M Buy
1,271,500
+142,311
+13% +$251K ﹤0.01% 1796
2023
Q3 		$1.73M Sell
1,129,189
-101,007
-8% -$174K ﹤0.01% 1950
2023
Q2 		$2.03M Buy
1,230,196
+711,396
+137% +$1.29M ﹤0.01% 1988
2023
Q1 		$591K Buy
518,800
+56,063
+12% +$48.6K ﹤0.01% 2793
2022
Q4 		$417K Sell
462,737
-438,063
-49% -$411K ﹤0.01% 3051
2022
Q3 		$1.05M Sell
900,800
-325,600
-27% -$368K ﹤0.01% 2466
2022
Q2 		$785K Buy
1,226,400
+1,192,100
+3,476% +$1.59M ﹤0.01% 2866
2022
Q1 		$90K Buy
34,300
+23,043
+205% +$67.3K ﹤0.01% 3812
2021
Q4 		$44K Sell
11,257
-178,412
-94% -$895K ﹤0.01% 3793
2021
Q3 		$827K Sell
189,669
-55,779
-23% -$219K ﹤0.01% 2651
2021
Q2 		$974K Buy
+245,448
New +$980K ﹤0.01% 2682
2021
Q1 		– Sell
-271,800
Closed -$1.45M – 3291
2020
Q4 		$1.45M Buy
+271,800
New +$1.63M ﹤0.01% 2306
2020
Q2 		– Sell
-294,051
Closed -$644K – 3418
2020
Q1 		$644K Buy
294,051
+215,051
+272% +$817K ﹤0.01% 2640
2019
Q4 		$460K Buy
+79,000
New +$411K ﹤0.01% 2936

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies's AQST Position: Q1 2026 in Review

Renaissance Technologies sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 414,400 shares — an estimated $2.68M sold.

Renaissance Technologies first reported a position in AQST in Q4 2019 and held it in 20 quarters. The position peaked at $5.86M in Q1 2024. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Renaissance Technologies reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Renaissance Technologies sold 414,400 Aquestive Therapeutics shares in Q1 2026, an estimated $2.68M.
  • Renaissance Technologies first reported a position in Aquestive Therapeutics in Q4 2019 and held it in 20 quarters.
  • Renaissance Technologies's Aquestive Therapeutics position peaked at $5.86M in Q1 2024.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.